Skip to main content
Erschienen in: Infection 1/2013

01.02.2013 | Clinical and Epidemiological Study

MRSA decolonization: success rate, risk factors for failure and optimal duration of follow-up

verfasst von: P. Kohler, A. Bregenzer-Witteck, G. Rettenmund, S. Otterbech, M. Schlegel

Erschienen in: Infection | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Methicillin-resistant Staphylococcus aureus (MRSA) decolonization is a widely established, though controversial part of many MRSA controlling strategies. The aim of this study was to evaluate our decolonization success rate, identify the risk factors for decolonization failure and determine the optimal duration of follow-up in our low MRSA prevalence setting (2.6 % of isolates).

Methods

Every patient with newly detected MRSA colonization or infection between January 2007 and December 2009 was recruited to the study. The MRSA strategy of our institution (a 700 bed tertiary hospital in eastern Switzerland) consists of a 5-day regimen of nasal mupirocin ointment, chlorhexidin mouth rinse and whole body wash with didecyldimonium chloride. Systemic antibiotics are usually not added to the regimen.

Results

We determined a MRSA decolonization success rate of 65 % (33/51) after a median follow-up of 13 months [i.e. a tripling of the spontaneous clearance rate of 22 % (6/27) in the non-decolonized group]. The most important risk factor for decolonization failure was colonization of the respiratory tract [odds risk (OR) 9.1, 95 % confidence interval (CI) 1.2–66.7], as well as isolation of MRSA spa-type 002 ([R 5.8, 95 % CI 1.0–33.3). Of all the episodes of MRSA recurrence, 88 % (14/16) were detected within 270 days after decolonization.

Conclusion

High MRSA decolonization success rates can be achieved without the routine use of oral antibiotics. A time period of 1 year after decolonization seems to be a reasonable duration of follow-up in our setting. We encourage other institutions to take into account local MRSA epidemiology (e.g. predominance of certain subtypes) for the management of MRSA patients.
Literatur
1.
Zurück zum Zitat Huang S, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis. 2003;36:281–5.PubMedCrossRef Huang S, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis. 2003;36:281–5.PubMedCrossRef
2.
Zurück zum Zitat Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect. 2001;48[Suppl A]:S9–14.PubMedCrossRef Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect. 2001;48[Suppl A]:S9–14.PubMedCrossRef
3.
Zurück zum Zitat Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev. 2003;(4):CD003340. Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev. 2003;(4):CD003340.
4.
Zurück zum Zitat Lucet JC, Regnier B. Screening and decolonization: does methicillin-susceptible Staphylococcus aureus hold lessons for methicillin-resistant S. aureus? Clin Infect Dis. 2010;51(5):585–90.PubMedCrossRef Lucet JC, Regnier B. Screening and decolonization: does methicillin-susceptible Staphylococcus aureus hold lessons for methicillin-resistant S. aureus? Clin Infect Dis. 2010;51(5):585–90.PubMedCrossRef
5.
Zurück zum Zitat Robicsek A, Beaumont JL, Thomson RB Jr, Govindarajan G, Peterson LR. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol. 2009;30:623–32.PubMedCrossRef Robicsek A, Beaumont JL, Thomson RB Jr, Govindarajan G, Peterson LR. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol. 2009;30:623–32.PubMedCrossRef
6.
Zurück zum Zitat Dow G, Field D, Mancuso M, Allard J. Decolonization of methicillin-resistant Staphylococcus aureus during routine hospital care: efficacy and long-term follow-up. Can J Infect Dis Med Microbiol. 2010;21(1):38–44.PubMed Dow G, Field D, Mancuso M, Allard J. Decolonization of methicillin-resistant Staphylococcus aureus during routine hospital care: efficacy and long-term follow-up. Can J Infect Dis Med Microbiol. 2010;21(1):38–44.PubMed
7.
Zurück zum Zitat Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis. 2009;48:922–30.PubMedCrossRef Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis. 2009;48:922–30.PubMedCrossRef
8.
Zurück zum Zitat Buehlmann M, Frei R, Fenner L, Dangel M, Fluckiger U, Widmer AF. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol. 2008;29(6):510–6.PubMedCrossRef Buehlmann M, Frei R, Fenner L, Dangel M, Fluckiger U, Widmer AF. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol. 2008;29(6):510–6.PubMedCrossRef
9.
Zurück zum Zitat Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2000;31(6):1380–5.PubMedCrossRef Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2000;31(6):1380–5.PubMedCrossRef
10.
Zurück zum Zitat Institut für Klinische Mikrobiologie und Immunologie (IKMI) Antibiotika-Empfindlichkeit der wichtigsten Gram-positiven Bakterien und Gram-negativen Non-Enterobacteriaceae. St. Gallen. 2007. Available at: www.ikmi.ch. Institut für Klinische Mikrobiologie und Immunologie (IKMI) Antibiotika-Empfindlichkeit der wichtigsten Gram-positiven Bakterien und Gram-negativen Non-Enterobacteriaceae. St. Gallen. 2007. Available at: www.​ikmi.​ch.
11.
Zurück zum Zitat Verhoef J, Beaujean D, Blok H, Baars A, Meyler A, van der Werken C, Weersink A. A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1999;18(7):461–6.PubMedCrossRef Verhoef J, Beaujean D, Blok H, Baars A, Meyler A, van der Werken C, Weersink A. A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1999;18(7):461–6.PubMedCrossRef
12.
Zurück zum Zitat Witteck A, Rettenmund G, Schlegel M. MRSA admission screening in a low prevalence setting—much ado about nothing? Swiss Med Wkly. 2011;7(141):w13217. Witteck A, Rettenmund G, Schlegel M. MRSA admission screening in a low prevalence setting—much ado about nothing? Swiss Med Wkly. 2011;7(141):w13217.
13.
Zurück zum Zitat Mathews AA, Thomas M, Appalaraju B, Jayalakshmi J. Evaluation and comparison of tests to detect methicillin-resistant Staphylococcus aureus. Indian J Pathol Microbiol. 2010;53(1):79–82.PubMedCrossRef Mathews AA, Thomas M, Appalaraju B, Jayalakshmi J. Evaluation and comparison of tests to detect methicillin-resistant Staphylococcus aureus. Indian J Pathol Microbiol. 2010;53(1):79–82.PubMedCrossRef
14.
Zurück zum Zitat Brown DF, Edwards DI, Hawkey PM, et al. Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother. 2005;56(6):1000–8.PubMedCrossRef Brown DF, Edwards DI, Hawkey PM, et al. Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother. 2005;56(6):1000–8.PubMedCrossRef
15.
Zurück zum Zitat Fleisch F, Oechslin EC, Gujer AR, Ritzler E, Imhof A, Ruef C, Reinhart WH. Transregional spread of a single clone of methicillin-resistant Staphylococcus aureus between groups of drug users in Switzerland. Infection. 2005;33(4):273–7.PubMedCrossRef Fleisch F, Oechslin EC, Gujer AR, Ritzler E, Imhof A, Ruef C, Reinhart WH. Transregional spread of a single clone of methicillin-resistant Staphylococcus aureus between groups of drug users in Switzerland. Infection. 2005;33(4):273–7.PubMedCrossRef
16.
Zurück zum Zitat Fenner L, Widmer AF, Dangel M, Frei R. Distribution of spa types among meticillin-resistant Staphylococcus aureus isolates during a 6 year period at a low-prevalence University Hospital. J Med Microbiol. 2008;57(Pt 5):612–6.PubMedCrossRef Fenner L, Widmer AF, Dangel M, Frei R. Distribution of spa types among meticillin-resistant Staphylococcus aureus isolates during a 6 year period at a low-prevalence University Hospital. J Med Microbiol. 2008;57(Pt 5):612–6.PubMedCrossRef
17.
Zurück zum Zitat Ammerlaan HS, Kluytmans JA, Berkhout H, Buiting A, de Brauwer EI, van den Broek PJ, van Gelderen P, Leenders SA, Ott A, Richter C, Spanjaard L, Spijkerman IJ, van Tiel FH, Voorn GP, Wulf MW, van Zeijl J, Troelstra A, MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: effectiveness of a national guideline. J Antimicrob Chemother. 2011;66(10):2409–17.PubMedCrossRef Ammerlaan HS, Kluytmans JA, Berkhout H, Buiting A, de Brauwer EI, van den Broek PJ, van Gelderen P, Leenders SA, Ott A, Richter C, Spanjaard L, Spijkerman IJ, van Tiel FH, Voorn GP, Wulf MW, van Zeijl J, Troelstra A, MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: effectiveness of a national guideline. J Antimicrob Chemother. 2011;66(10):2409–17.PubMedCrossRef
18.
Zurück zum Zitat Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D, European Staphylococcal Reference Laboratory Working Group. Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med. 2010;7(1):e1000215.PubMedCrossRef Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D, European Staphylococcal Reference Laboratory Working Group. Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med. 2010;7(1):e1000215.PubMedCrossRef
19.
Zurück zum Zitat Pan A, Lee A, Cooper B, Chalfine A, Daikos G, Garilli S, Malhotra-Kumar S, Martinez JA, Patroni A, Harbarth S, MOSAR-04 Study Team. Risk factors for previously unknown methicillin-resistant Staphylococcus aureus (MRSA) carriage on admission to 13 surgical wards in Europe. BMC Proc. 2011;5[Suppl 6]:O85.CrossRef Pan A, Lee A, Cooper B, Chalfine A, Daikos G, Garilli S, Malhotra-Kumar S, Martinez JA, Patroni A, Harbarth S, MOSAR-04 Study Team. Risk factors for previously unknown methicillin-resistant Staphylococcus aureus (MRSA) carriage on admission to 13 surgical wards in Europe. BMC Proc. 2011;5[Suppl 6]:O85.CrossRef
20.
Zurück zum Zitat Tiemersma EW, Bronzwaer SL, Lyytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N, Monen J, Witte W, European Antimicrobial Resistance Surveillance System Participants. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10(9):1627–34.PubMedCrossRef Tiemersma EW, Bronzwaer SL, Lyytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N, Monen J, Witte W, European Antimicrobial Resistance Surveillance System Participants. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10(9):1627–34.PubMedCrossRef
21.
Zurück zum Zitat Hudson LO, Murphy CR, Spratt BG, Enright MC, Terpstra L, Gombosev A, Hannah P, Mikhail L, Alexander R, Moore DF, Huang SS. Differences in methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from pediatric and adult patients from hospitals in a large California County. J Clin Microbiol. 2012;50(3):573–9. Hudson LO, Murphy CR, Spratt BG, Enright MC, Terpstra L, Gombosev A, Hannah P, Mikhail L, Alexander R, Moore DF, Huang SS. Differences in methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from pediatric and adult patients from hospitals in a large California County. J Clin Microbiol. 2012;50(3):573–9.
22.
Zurück zum Zitat Vindel A, Cuevas O, Cercenado E, Marcos C, Bautista V, Castellares C, Trincado P, Boquete T, Pérez-Vázquez M, Marín M, Spanish Group for the Study of Staphylococcus. Methicillin-resistant Staphylococcus aureus in Spain: molecular epidemiology and utility of different typing methods. J Clin Microbiol. 2009;47(6):1620–7.PubMedCrossRef Vindel A, Cuevas O, Cercenado E, Marcos C, Bautista V, Castellares C, Trincado P, Boquete T, Pérez-Vázquez M, Marín M, Spanish Group for the Study of Staphylococcus. Methicillin-resistant Staphylococcus aureus in Spain: molecular epidemiology and utility of different typing methods. J Clin Microbiol. 2009;47(6):1620–7.PubMedCrossRef
23.
Zurück zum Zitat Larsson AK, Gustafsson E, Nilsson AC, Odenholt I, Ringberg H, Melander E. Duration of methicillin-resistant Staphylococcus aureus colonization after diagnosis: a four-year experience from southern Sweden. Scand J Infect Dis. 2011;43(6–7):456–62.PubMedCrossRef Larsson AK, Gustafsson E, Nilsson AC, Odenholt I, Ringberg H, Melander E. Duration of methicillin-resistant Staphylococcus aureus colonization after diagnosis: a four-year experience from southern Sweden. Scand J Infect Dis. 2011;43(6–7):456–62.PubMedCrossRef
24.
Zurück zum Zitat Ammerlaan HS, Kluytmans JA, Berkhout H, Buiting A, de Brauwer EI, van den Broek PJ, van Gelderen P, Leenders SA, Ott A, Richter C, Spanjaard L, Spijkerman IJ, van Tiel FH, Voorn GP, Wulf MW, van Zeijl J, Troelstra A, MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: determinants of treatment failure. J Antimicrob Chemother. 2011;66(10):2418–24.PubMedCrossRef Ammerlaan HS, Kluytmans JA, Berkhout H, Buiting A, de Brauwer EI, van den Broek PJ, van Gelderen P, Leenders SA, Ott A, Richter C, Spanjaard L, Spijkerman IJ, van Tiel FH, Voorn GP, Wulf MW, van Zeijl J, Troelstra A, MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: determinants of treatment failure. J Antimicrob Chemother. 2011;66(10):2418–24.PubMedCrossRef
25.
Zurück zum Zitat Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, Kiss A. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis. 2007;44(2):178–85.PubMedCrossRef Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, Kiss A. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis. 2007;44(2):178–85.PubMedCrossRef
26.
Zurück zum Zitat Marschall J, Muehlemann K. Duration of MRSA-carriage, according to risk factors for acquisition. Infect Control Hosp Epidemiol. 2006;27(11):1206–12.PubMedCrossRef Marschall J, Muehlemann K. Duration of MRSA-carriage, according to risk factors for acquisition. Infect Control Hosp Epidemiol. 2006;27(11):1206–12.PubMedCrossRef
Metadaten
Titel
MRSA decolonization: success rate, risk factors for failure and optimal duration of follow-up
verfasst von
P. Kohler
A. Bregenzer-Witteck
G. Rettenmund
S. Otterbech
M. Schlegel
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Infection / Ausgabe 1/2013
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-012-0290-1

Weitere Artikel der Ausgabe 1/2013

Infection 1/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.